BEUDAMED
    FDA Adverse Event Injury Summary report: N

    HEMOLUNG RAS

    MDR report key: 16211822 · Received January 19, 2023

    Report

    Report Number
    3009763347-2023-00076
    Event Type
    Injury
    Date Received
    January 19, 2023
    Date of Event
    October 1, 2020
    Report Date
    January 19, 2023
    Manufacturer
    ALUNG TECHNOLOGIES, INC.
    Product Code
    QLN
    UDI-DI
    00850046004346
    PMA / PMN Number
    DEN210006
    Adverse Event
    Yes
    Report Source
    Manufacturer report
    Reporter Location
    FL, US
    Reporter Occupation
    OTHER HEALTH CARE PROFESSIONAL
    Health Professional
    Yes

    Narratives

    Additional Manufacturer Narrative · 0

    THIS PATIENT INFORMATION WAS NOT PROVIDED. ALUNG TECHNOLOGIES, INC. MANUFACTURES THE HEMOLUNG RAS AND CATHETER. THE INCIDENT OCCURRED IN (B)(6). MEDICAL INTERVENTION WAS NECESSARY TO AVOID FURTHER PATIENT INJURY. THROUGH REVIEW OF THE EXPANDED ACCESS FORM, THE PATIENT EXPERIENCED ANEMIA. IT WAS NOTED THAT THE PATIENT RECEIVED EIGHT UNITS OF BLOOD, 2 UNITS THAWED PLASMA, AND 2 UNITS PLT. THERAPY WAS NOT DISCONTINUED AS A RESULT OF THIS ISSUE. THE DATA LOG FROM THERAPY HAS BEEN RETRIEVED AND REVIEWED BY BOTH CLINICAL AND SOFTWARE ENGINEERING STAFF. NO ABNORMALITIES WERE NOTED WITHIN THE CO2 REMOVAL AND BLOOD FLOW GRAPHS. THERAPY WAS PROVIDED AS INTENDED. NO CAPA WAS OPENED BECAUSE OF THIS EVENT. ANEMIA IS A KNOWN COMPLICATION THAT CAN OCCUR DURING EXTRACORPOREAL THERAPY. EXAMINATION OF THE CONTROLLER DATA LOG SHOWS THAT THERAPY WAS PROVIDED AS INTENDED. ALUNG TECHNOLOGIES, INC. WILL CONTINUE TO MONITOR ANY ISSUES AS THEY ARE REPORTED. THIS MDR IS BEING FILED IN RESPONSE TO A RETROSPECTIVE VIEW OF ALL ALUNG TECHNOLOGIES, INC. COMPLAINTS, WHICH IDENTIFIED THAT THE REPORTING DECISION FOR THIS COMPLAINT WAS NOT CORRECT. THIS MDR IS BEING FILED RETROSPECTIVELY TO CORRECT THE ERROR IN THE REPORTING DECISION.

    Description of Event or Problem · 0

    ALUNG TECHNOLOGIES, INC. RECEIVED A REPORT OF A PATIENT EXPERIENCING ANEMIA, BOTH SEVERE AND ACUTE DURING EUA HEMOLUNG THERAPY. EIGHT UNITS OF BLOOD, 2 UNITS OF PLASMA, AND 2 UNITS OF PLT WERE PROVIDED TO THE PATIENT OVER 3 DAYS. HEMOLUNG THERAPY WAS NOT DISCONTINUED AS A RESULT OF THIS EVENT.

    Devices

    Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
    363319 HEMOLUNG RAS EXTRACORPOREAL SYSTEM FOR CARBON DIOXIDE REMOVAL FOR THE TREATMENT OF COVID-19 QLN ALUNG TECHNOLOGIES, INC. HL-CR4-01-000 00850046004346

    Patients

    Seq Age Sex Outcome Treatment
    1 76 YR Male Required Intervention| L